Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Research reveals Eli Lilly's GLP-1 drug, tirzepatide, temporarily suppresses food cravings in a patient's brain reward center. While initial effects were promising, the impact faded over time. Results ...

Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing ...

In a remarkable turn of events within the pharmaceutical industry, Eli Lilly's tirzepatide has overtaken Merck's Keytruda to become the world’s best-selling medicine. This shift highlights not only ...

By volume, Augmentin was way higher than Mounjaro with 5,784 units sold during October, compared to just 85 units sale of ...

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

Eli Lilly's Mounjaro became India's highest-selling drug in October with ₹100 crore sales. The anti-obesity treatment now ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Merck, which has claimed ...

Eli Lilly has shared positive results from a Phase II clinical trial (NCT06230523) evaluating eloralintide, an investigational once-weekly, selective amylin receptor, in adults with obesity or ...

Eli Lilly's weight-loss therapy Mounjaro became India's top-selling drug by value in October, data showed on Friday, ...

Eli Lilly LLY reported 54% revenue growth in the third quarter as its diabetes and obesity drug tirzepatide (Mounjaro/Zepbound) continued to gain share globally, and management raised top- and ...